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ABSTRACT Allosteric modulators and mutations that slow AMPAR desensitization have additional effects on deactivation and
agonist potency. We investigated whether these are independent actions or the natural consequence of slowing desensitization.
Effects of cyclothiazide (CTZ), trichlormethiazide (TCM), and CX614 were compared at wild-type GluR1 and ‘‘nondesensitizing’’
GluR1-L497Y mutant receptors by patch-clamp recording with ultrafast perfusion. CTZ, TCM, or L/Y mutation all essentially
blocked GluR1 desensitization; however, the effects of L/Y mutation on deactivation and glutamate EC50 were three to ﬁve times
greater than for modulators. CTZ and TCM further slowed desensitization of L/Y mutant receptors but paradoxically accelerated
deactivation and increased agonist EC50. Results indicate that CTZ and TCM target deactivation and agonist potency
independently of desensitization, most likely by modifying agonist dissociation (koff). Conversely, CX614 slowed desensitization
and deactivation without affecting EC50 in both wild-type and L/Y receptors. The S750Q or combined L497Y-S750Q mutations
abolished all CTZ andTCMactionswithout disruptingCX614 activity. Notably, theS/Qmutation also restored L/Y deactivation and
EC50 to wild-type levels without restoring desensitization, further demonstrating that desensitization can be modulated
independently of deactivation and EC50 by mutagenesis and possibly by allosteric modulators.
INTRODUCTION
AMPA-type glutamate receptors (AMPARs) are ligand-
gated ion channels that represent the principal mediators of
fast excitatory synaptic transmission in the mammalian CNS.
The dysfunction of AMPARs has been linked to Alzheimer’s
disease, depression, epilepsy, stroke, and neurodegenerative
disease (1,2). Their implication in these various neuropa-
thologies makes them attractive targets for the rational
design and development of novel therapeutics.
AMPAR-mediated synaptic currents are exceedingly brief
(;1–2 ms), reﬂecting the transient elevation of glutamate in
the synaptic cleft (3,4) and rapid inactivation of AMPARs by
the combined processes of deactivation and desensitization
(5–7). Deactivation is measured by the decay of current after
the removal of agonist, which follows an exponential time
course having a time constant (tdeact) of 0.5–2 ms. Desen-
sitization is measured by the decay of current in the con-
tinuous presence of agonist and has a somewhat slower time
constant (tdes) on the order of 1–10 ms (5,6,8). Both de-
sensitization and deactivation are empirical measures of
current decay from the open state, and so both measures
necessarily involve the rate of channel closing (a). Beyond
that, it remains unclear to what extent the underlying rates of
agonist dissociation (koff) and isomerization to the desensi-
tized conformation (kdes) are truly independent of one
another. Nonetheless, because these rates collectively govern
the magnitude and time course of synaptic transmission, an
objective in the development of novel AMPAR modulators
has been to target these processes selectively.
The molecular mechanisms of AMPAR gating and desen-
sitization are the subject of intense investigation. Structural
studies suggest that glutamate binds within an agonist-bind-
ing clamshell (9). The binding domains are linked to one an-
other in a back-to-back dimer conﬁguration (10,11) and held
together in part by a salt-bridge hydrogen bond network at
the dimer interface (12). AMPAR activation involves closure
of the upper and lower lobes of the binding pocket around
the agonist, which pulls against the rigid dimer interface to
cause channel opening by rotational rearrangement of the
transmembrane domains (13). Deactivation is thought to rep-
resent simply the reverse of this process, whereas desensi-
tization is related to instability of the dimer interface contacts
that are necessary to link the agonist-binding and transmem-
brane domains (11–14).
Allosteric modulators bind remotely but inﬂuence the
agonist binding site or agonist-induced conformational rear-
rangements associated with channel gating (7,15–21). Inter-
est in AMPAR allosteric modulators began in earnest with
the discovery that cyclothiazide (CTZ) potentiates AMPAR
currents in hippocampal neurons by slowing desensitization
(21,22). CTZ binds within and stabilizes the glutamate
receptor (GluR) dimer interface (11) and owes its preference
for AMPAR-ﬂip isoforms (7,22,23) to a single serine residue
(S750) in the ﬂip/ﬂop domain (7). In addition to slowing
desensitization, CTZ also slows AMPAR deactivation (7)
and increases the apparent afﬁnity for activation by agonist
(24). These secondary actions of CTZ might be an indirect
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consequence of slowing desensitization or a direct effect of
CTZ on agonist dissociation. The question is complicated to
the extent that desensitization contributes to deactivation and
limits agonist potency by preventing channel activation at
low agonist concentrations (25,26).
To answer this question we used a combinatorial ap-
proach that employed a ‘‘nondesensitizing’’ AMPAR. Similar
to CTZ, mutation of a leucine to a tyrosine at position 497 of
GluR1 (27) (GluR2-L483Y (28)) greatly reduces AMPAR
desensitization. The GluR1-L497Y receptor allowed us to
discriminate between drug effects that were a consequence of
blocking desensitization and those effects that were unique
and separable from desensitization. The actions of a related
benzothiadiazide, trichlormethiazide (TCM), and an unrelated
Ampakine, 2H,3H,6aH-pyrrolidino[29,19-39,29]1,3-oxazino[69,
59-5,4]benzo[e]1,4dioxan-10-one (CX614), were also exam-
ined. GluR1-wt and GluR1-L497Y receptors were expressed
in HEK 293 cells, and drug effects on measures of deac-
tivation, desensitization, and agonist EC50 were determined
using ultrafast solution exchange. An additional mutation,
GluR1-S750Q (7), was used to conﬁrm benzothiadiazide
binding at the dimer interface and resulted in identiﬁcation of
S750 as a pivotal linkage that connects the L497Y mutation
to the agonist-binding pocket. Results indicate that desen-
sitization and deactivation can be selectively targeted, at least
by site-directedmutagenesis, which suggests that future mod-
ulators may also be capable of such selectivity. Actions of
modulators alone, and interactions between modulators and
mutations on channel gating, are characterized in an effort to
offer potential strategies for targeting speciﬁc AMPAR gat-
ing transitions.
MATERIALS AND METHODS
Materials
Ultrapure salts and chemicals were purchased from Sigma (St. Louis, MO).
Cell Culture
Human Embryonic Kidney 293 ﬁbroblasts (HEK293, CRL, ATCC,
Manassas, VA) were cultured in minimal essential medium (MEM) sup-
plemented with 10% fetal bovine serum and 2 mM Glutamax (Life
Technologies, Rockville, MD). Cells were incubated at 37C in a 5% CO2
environment. Cells were plated into 25 cm2 Falcon ﬂasks and passed twice
weekly to fresh ﬂasks without reaching conﬂuence.
Transfections
Cells intended for transfection and subsequent recording were plated to
poly-D-lysine–coated 35-mm NUNC dishes at a density of 80,000 cells/ml
and transfected the following day using Lipofectamine 2000 reagents (Life
Technologies). Cells were cotransfected with EGFP at a 9:1 ratio. cDNA
plasmids containing GluR1, GluR1-L497Y, GluR1-S750Q, or GluR1-
L497Y/S750Q were combined with Lipofectamine reagents for a ﬁnal
concentration of 1 mg/ml cDNA per 35-mm NUNC dish. Transfected
cells were incubated for 36–72 h before use for electrophysiological
recordings.
Patch-clamp recordings
Cells were continuously superfused with a standard extracellular solution
containing (in mM): 150 NaCl, 3 KCl, 5 HEPES, 1 MgCl2, 1.8 CaCl2, 10
glucose, and 0.1 mg/ml phenol red, with an adjusted pH of 7.3. Transfected
cells were identiﬁed by ﬂuorescent expression of EGFP. Recording
microelectrodes were fabricated from thin-walled borosilicate glass capillary
tubes (TW150, World Precision Instruments, Sarasota, FL). Electrode open-
tip resistance was typically 2–4MVwhen ﬁlled with an intracellular solution
comprised of (in mM): 135 CsCl, 10 CsF, 10 HEPES, 5 EGTA, 1 MgCl2, 0.5
CaCl2, pH 7.2, and 295 mOsm. Outside-out patch recordings were per-
formed in voltage-clamp mode at a holding potential of 70 mV using an
Axopatch 200B ampliﬁer (Axon Instruments, Foster City, CA). Current
signals were ﬁltered at 2–5 kHz with an eight-pole Bessel ﬁlter (Cygnus
Technologies, Delaware Watergap, PA), digitized at 20 kHz, and stored on a
Macintosh PowerPC-G3 computer using an ITC-16 interface (Instrutech,
Port Washington, NY) under the control of the data acquisition and analysis
program Synapse (Synergy Research, Silver Spring, MD). All recordings
were performed at room temperature (20–22C).
Ultrafast solution exchange
All recordings were conducted in the outside-out patch conﬁguration. Ultra-
fast solution exchange was achieved by using an LSS-3100 piezotranslator
(Burleigh Instruments, Fisher, NY). Control and agonist solutions were
driven simultaneously at a rate of 0.25 ml/min through two parallel barrels of
a u-tube having a tip diameter ;200 mm. Allosteric modulators were pre-
applied through the control barrel. Membrane patches were positioned in the
control stream near the solution interface, and a piezotranslator was used to
rapidly move the u-tube ;100 mm such that the solution interface passed
over the patch. The timing and rate of solution exchange were determined
by open-tip junction currents at the conclusion of all recordings and were
typically ,200 ms (10–90% rise time); these were based on current de-
ﬂections produced by a 5% change in NaCl concentration. Representative
ﬁgure traces as well as those used for kinetic analyses were averages of 5–10
consecutive responses. Time constants for deactivation (tdeact) and desen-
sitization (tdes) were derived from one or two exponential ﬁts as required
using a least-squares ﬁtting algorithm. Current decays were ﬁt from 60% to
95% of peak to steady state. Glutamate was prepared as 1 M stock solution
at neutral pH and added to extracellular solutions by serial dilutions as
required. CTZ, TCM, and CX614 were prepared in DMSO and diluted in
external solution to ﬁnal concentrations of 100 mM, 500 mM, and 100 mM,
respectively (ﬁnal DMSO concentration 0.5%). DMSO controls up to 10
times the concentrations present in drug solutions did not alter deactivation
or desensitization kinetics in the absence of drug.
Statistical analyses
Mean EC50 and kinetic measures of deactivation and desensitization were
compared using a one-factor ANOVA. Post-hoc analyses employed two-
tailed Student’s t-tests with Bonferroni correction (where applicable). Paired
t-tests were employed in some cases to compare pre- and postdrug measures
from the same patches. Statistical signiﬁcance levels are indicated in the
ﬁgure legends. EC50 values were determined from best-ﬁts of the logistic
equation I ¼ Imax/(1 1 (EC50/(GLU))nH), where I is the current at a given
agonist concentration, Imax is the maximal current at saturation, EC50 is the
glutamate concentration giving half-maximal current, and nH is the Hill
coefﬁcient. A least-squares algorithm from KaleidaGraph software was used
to generate curve ﬁts (Synergy Software, Reading, PA). Best-ﬁtting nH
values were generally near unity (1.2–1.4). The number of independent ob-
servations from different patches is indicated (n) within ﬁgures.
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Computational modeling of modulator and
mutation effects
Computational models were constructed, and simulations were tested, using
AxoGraph software (Axon Instruments). Several kinetic schemes have been
used tomodelAMPARbehavior (7,25,29), and theunderlyingassumptionsof
modeling AMPAR behavior have been well described (29,30). We adopted
the 4-site scheme of Robert and Howe (29), which was simpliﬁed by
excluding secondary desensitized states. Brieﬂy, the model assumes that 1),
AMPARs are tetrameric channels (2,31,32) that possess four agonist binding
sites (9,10) and exhibit three intermediate conductance levels (31,33), 2),
agonist binding initiates either channel activation or desensitization, and
3), the decay during prolonged agonist pulses represents receptor entry
into desensitized states. The parameters of the models were optimized to
simultaneously reproduce the values of activation (tact), deactivation (tdeact),
desensitization (tdes), and agonist potency (EC50) that were observed ex-
perimentally for wild-type, modulator-bound, andmutant receptors; the latter
required iterative changes to one or more rate constants: kon/koff, b/a, or kdes/
kres. Initially, rate constants were modiﬁed individually, and the effects of
these changes on channel behavior were recorded. Subsequent modiﬁcations
to multiple rate constants were then combined in an iterative manner to arrive
at an optimal solution (seeTable 2). Simpler two-site kinetic schemes required
similar solutions except that the changes were quantitatively different.
RESULTS
CTZ and L497Y mutation block desensitization
and slow deactivation
Many effects of CTZ and the L497Y mutation on GluR
function are documented, but it is difﬁcult to compare these
various results from different preparations, methods, and lab-
oratories (7,22,23,27,34,35). Speciﬁcally, we sought to com-
pare (quantitatively) the effects of CTZ and L497Y mutation
on desensitization, deactivation, and agonist potency (EC50)
in GluR1 AMPARs. Our initial experiments therefore rep-
licated ﬁndings from other sources not only to conﬁrm the
ﬁndings but also to make them quantitatively comparable for
subsequent studies (Fig. 1). Consistent with previous reports,
homomeric wild-type GluR1-ﬂip channels in outside-out
membrane patches deactivated in ,1 ms (Fig. 1 C) and
desensitized to ,1% of peak within 2–3 ms (Fig. 1 A).
Preapplication of 100 mM CTZ or insertion of a leucine-to-
tyrosine (L/Y) mutation at position 497 of the mature protein
prevented desensitization during 50-ms pulses of 10 mM
glutamate. Prolonged exposure to glutamate for up to 2 s
typically produced ,25% decay to steady state in GluR1 1
CTZ and L/Y mutant receptors (Fig. 1 B, Table 1). Although
desensitization is slowed extensively by CTZ and the L497Y
mutation, as indicated in Fig. 1, receptors did still desensitize
(see Table 1 for values). Differences in the time course of
deactivation were obvious from the relaxation kinetics after
glutamate removal; decay of currents for GluR11CTZ
appeared much faster than GluR1-L497Y. To characterize
deactivation kinetics more precisely, and for comparison to
wild-type GluR1, brief 1-ms exposure and rapid removal of
10 mM glutamate were used to minimize wild-type desen-
sitization and to focus on the faster processes of channel
closing (a) and agonist dissociation (koff). These effects are
depicted in Fig. 1 C and summarized in Table 1. Deactiva-
tion time constants (tdeact) were signiﬁcantly slower than
wild type in both cases (P, 0.001 unpaired Student’s t-test),
but more so for the L/Y mutant than for GluR1 1 CTZ.
Preincubation of GluR1 receptors with 100 mM CTZ slowed
receptor deactivation by 2.4-fold, whereas the L497Y mu-
tation slowed GluR1 deactivation by more than 13-fold com-
pared to wild type. These values are similar to those reported
elsewhere (7,34). Activation rates were evaluated by com-
paring the current onset time constants (tact) of receptors at
glutamate concentrations ranging from 0.3 to 3 mM. As ex-
pected, activation rates were concentration dependent; the re-
lation between concentration and activation was not different
between groups, indicating that rates of agonist binding (kon)
and channel opening (b) were not modiﬁed by these
manipulations.
FIGURE 1 Effects of CTZ and L497Y mutation on AMPAR function. (A)
Fast desensitization of GluR1 receptors was measured during 50-ms pulses
of 10 mM glutamate (arrow indicates peak of GluR1 wild-type current,
WT). Desensitization was absent after preexposure (.10 s) to 100 mMCTZ
or introduction of the L497Y mutation at the dimer interface. The GluR1-
L497Y mutant trace was normalized to allow for direct comparison of decay
kinetics after the removal of glutamate. Traces here and in subsequent ﬁgures
are averages of 5–10 consecutive responses. (B) Although CTZ and the L497Y
mutation effectively alleviated desensitization during 50-ms pulses, partial,
slow desensitization was apparent during longer 2-s agonist pulses. (C)
Deactivation after 1-ms pulses of 10 mM glutamate. Fast deactivation of wild-
type GluR1wasmoderately slower after preincubation with CTZ. Introduction
of the L497Y mutation slowed channel deactivation more extensively. The
L497Y mutant currents were normalized for comparison of kinetics. Identical
resultswere obtained ifCTZwaspreappliedbut absent during the agonist pulse,
as in the traces shown, or by coapplication of CTZ after preexposure. (D)
Concentration-response curves for wild-type GluR1 in the absence and
presence of 100 mM CTZ and for GluR1-L497Y. Data are ﬁt by the logistic
equation (see Methods). Error bars represent SEM for individual data points.
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CTZ and L497Y mutation enhance agonist potency
Immediately after the application of glutamate, receptors
begin to desensitize at a rate of ;450 s1 (tdes ;2.2 ms).
This limits their contribution to the peak response and
theoretically should do so most profoundly at lower agonist
concentrations where agonist-binding rates (kon) are equiv-
alent to or slower than the rate of desensitization. Thus,
blocking entry into the desensitized states should facilitate
receptor activation and increase the apparent afﬁnity for
glutamate. To conﬁrm this relation, we compared the effects
of CTZ and the L/Y mutation on the glutamate concentration-
response relation. The curves were derived using a 10 mM
maximum concentration of glutamate and sequential appli-
cation of six lower agonist concentrations before returning to
the maximum concentration to assess rundown; data from
patches that exhibited .20% rundown of the maximal
currents were excluded. Peak response data were normalized
to the maximal concentration, plotted as a function of
glutamate concentration, and ﬁt by a logistic equation (see
Methods). Best-ﬁtting EC50 values are given in Table 1.
Notably, even though both conditions achieved near-
complete block of desensitization, CTZ produced only a
9.4-fold increase in agonist potency, whereas the L497Y
mutation provided nearly a 40-fold increase in agonist
potency relative to wild-type controls (Figs. 1 D and 2 F and
Table 1). This more pronounced effect of the L497Y mu-
tation on agonist potency was paralleled by slower deacti-
vation rates (Figs. 1 C and 2 E). Although both CTZ and the
L/Y mutation produced equivalent block of desensitization,
their additional effects on deactivation and EC50 were
evidently very different.
Effects of CTZ on L497Y mutant AMPARs
The quantitatively different effects of CTZ and the L/Y muta-
tion on deactivation and agonist EC50 could be explained
in one of two ways. 1), Both CTZ and the L/Y mutation have
independent actions on desensitization, deactivation, and
agonist binding. Their varied effects are best explained by a
difference in efﬁcacy for deactivation and agonist afﬁnity. 2),
Slowing deactivation and lowering the EC50 is a conse-
quence of blocking desensitization for both GluR1 1 CTZ
and L/Y receptors, but only CTZ has an additional negative
allosteric effect that increases receptor deactivation and de-
creases the apparent afﬁnity for agonist.
To determine which of these explanations was valid, we
examined the effects of CTZ on L/Y mutant receptors. L/Y
mutant receptors showed little desensitization during 50-ms
agonist pulses in the absence or presence of CTZ. Longer
agonist pulses (2 s) allowed L/Y receptors to desensitize to
;75% of their peak currents (Fig. 2 B, see Table 1 for
values). This residual desensitization was blocked by pre-
application of 100 mMCTZ (Fig. 2 B) and was accompanied
by an unexpected threefold faster deactivation of L497Y
mutant receptors (Fig. 2, C–E). CTZ also produced a right-
ward shift in the glutamate concentration-response curve
(Fig. 2, D–F); EC50 values were sixfold higher after
preincubation with CTZ. All CTZ effects were reversed by
prolonged washout of the drug. In summary, CTZ further
slowed GluR1-L497Y receptor desensitization but para-
doxically accelerated receptor deactivation and decreased
agonist potency. This result indicates that CTZ and the L/Y
mutation effects are additive with respect to desensitization
but competitive with respect to deactivation and EC50. Such
competition, albeit only for the latter effects, implies con-
vergence at a common site or process that could result from
CTZ binding in proximity to the L/Y residue (11) or at an-
other unknown site. We therefore questioned whether the non-
competitive and competitive effects might be mediated by
CTZ binding to multiple sites.
TABLE 1 Mutation and drug effects on functional measures
Control 1 CTZ 1 TCM 1 CX614
GluR1-wt
tdes 2.2 6 0.1 ND 14 6 1* 7.1 6 0.3*
y
tdeact 0.9 6 0.1 2.2 6 0.3 4.7 6 0.6 6.4 6 1.3
y
EC50 779 6 72 83 6 13 178 6 13 657 6 98
Iss (%) , 1 . 95 86 6 1 39 6 4
GluR1-L497Y
tdes ND ND ND ND
tdeact 12 6 1 4.4 6 0.6 5.4 6 0.6 22 6 1
y
EC50 20 6 4 121 6 16 68 6 18 24 6 6
Iss (%) . 95 . 95 . 95 . 95
GluR1-S750Q
tdes 1.6 6 0.1 1.6 6 0.1 1.3 6 0.1 4.2 6 0.8*
y
tdeact 0.8 6 0.1 0.9 6 0.1 0.8 6 0.1 2.3 6 0.2
y
EC50 885 6 98 NA NA NA
Iss (%) , 1 , 1 2 6 1 16 6 1
GluR1-L497Y, S750Q
tdes 16 6 1* 16 6 1* NA 22 6 3*
y
tdeact 1.3 6 0.1 1.1 6 0.1 NA 2.2 6 0.2
y
EC50 1015 6 169 NA NA NA
Iss (%) 73 6 3 73 6 3 NA 69 6 1
Data from 10 mM glutamate-evoked currents with drug concentrations as
follows: cyclothiazide (CTZ, 100 mM), trichloromethiazide (TCM, 500
mM), CX614 (100 mM). t-values are given in ms, and EC50 values are
mM. Steady-state current amplitudes (Iss) during 50-ms glutamate pulses
are given as percentage of the corresponding peak current.ND denotes
responses having , 5% decay during 50 ms glutamate pulses. In some
cases, slow tdes values and steady-state ratios were estimated from 2-s
agonist pulses; values were 13 6 1 ms and 86 6 4% for WT 1 CTZ and
73 6 11 ms and 74 6 1% for L497Y. No desensitization was seen for
L497Y 1 CTZ within 2 s (Iss 101 6 2%).
NA, not analyzed.
*tdes values are given for the desensitizing fraction of the response; Iss
values for the same groups reﬂect the magnitude of the steady-state com-
ponent after 50-ms glutamate pulses.
yBiexponential; t-values are given for the weighted average of fast and
slow components. For GluR1 1 CX614 deactivation was 2.9 6 0.1 ms
(70%) and 16.7 6 0.5 ms (30%). In other cases the slow component was
,10%.
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Conﬁrmation of a single CTZ binding site in
L497Y receptors
To determine if these separate and opposing actions of CTZ
required multiple binding sites, we introduced the S750Q
mutation to both GluR1-wt and GluR1-L497Y constructs to
prevent CTZ from binding to its known binding site at the
dimer interface. Previous studies have shown that CTZ bind-
ing critically involves the SNQ residue at position 750 (in
GluR1), with serine (S) being the most active and glutamine
(Q) being inactive (7,11). The GluR1-S750Q single mutant
served as a control for these experiments. The GluR1-S750Q
mutant exhibited desensitization and deactivation kinetics
that were slightly faster than those of wild-type GluR1 (Fig.
3, A–C). GluR1-S750Q receptor rates of deactivation and
desensitization were consistent with those previously re-
ported (7). We also determined that the GluR1-S750Q re-
ceptor EC50 for glutamate was essentially unchanged from
GluR1-wt (see Table 1). Addition of the S750Q mutation to
the L/Y mutant resulted in several unexpected and signiﬁcant
changes in receptor phenotype, the most important of which
was elimination of both the positive and negative allosteric
effects of CTZ (Fig. 3, B–D). As expected, all CTZ effects on
GluR1-wt and L497Y mutant channels are made possible by
the S750 residue and therefore a single binding site.
Double mutant GluR1-L497Y/S750Q
The GluR1-L497Y/S750Q double mutant may represent the
keystone to understanding how CTZ and L/Y mutation
effects are both related to the S750 residue. Comparable to
the GluR2-L483Y/S754D mutant described by Sun et al.
(11), the GluR1-L497Y/S750Q mutant desensitized partially
during 50-ms glutamate pulses. The extent of desensitization
was far from complete, and its onset was sevenfold slower
than GluR1-wt but still fourfold faster than the L/Y parent
(see Table 1). Equilibrium (steady-state) currents during 50-ms
glutamate pulses were 73 6 3% of peak (Fig. 3 B). These
measures were notably similar to the equilibrium currents
recorded for WT1 CTZ and L497Y mutant receptors during
the 2-s agonist pulses (Fig. 1 B). Closer examination of the
GluR1-L497Y/S750Q double mutant indicated that deacti-
vation of this receptor was 10-fold faster than that in the L/Y
parent, and the EC50 for glutamate was ;40-fold higher.
Both of these values are remarkably comparable to GluR1-
wt and the GluR1-S750Q mutant (see Table 1 and Figs. 1 C,
2 C, and 3 C for comparison). These observations indicate
that effects of the L/Y mutation on deactivation and agonist
potency are not a consequence of slow desensitization but
occur independently. Moreover, this mutation demonstrates
that the S750 residue is required not only for all the effects
of CTZ but also for the effects of the L497Y mutation on
deactivation and agonist potency (Fig. 1, C and D, and 3 D).
Faster deactivation and reduced agonist potency of the CTZ
bound L/Y receptor implies that CTZ disrupts a direct or
indirect interaction between Y497 and S750 to promote
faster channel closing or agonist dissociation.
Effects of other allosteric modulators on L497Y
mutant receptors
The appearance of negative allosteric effects of CTZ (i.e.,
faster deactivation and reduced agonist potency) in addition
FIGURE 2 Inverse actions of CTZ at L497Y mutant receptors. (A) Current
traces showing desensitization kinetics of GluR1-L497Y in the absence and
presence of 100 mM CTZ during 50-ms pulses of 10 mM glutamate. CTZ
appeared to have little effect on L497Y currents during 50-ms pulses. (B)
GluR1-L497Y mutant receptor currents were nondesensitizing during 50-ms
pulses, but longer pulses (2 s) disclosed a partial and slowly desensitizing
response to 10 mM glutamate. The residual L497Y receptor desensitization
was alleviated after preincubation with 100 mM CTZ. (C) Deactivation
kinetics of GluR1-L497Y (1-ms pulse, 10 mM glutamate) in the absence and
presence of CTZ. Deactivation was about three times faster after preincubation
with 100 mMCTZ. (D) Concentration-response curves for the GluR1-L497Y
mutant in the absence and presence of CTZ. Data are ﬁt by the logistic
equation (see Methods); error bars represent SEM. (E, F) Summary bar plots
comparing deactivation time constants (E) and agonist potency (F) for GluR1-
wt and the GluR1-L497Y mutant receptors in the absence and presence of
CTZ. Error bars represent SEM. Numbers of observations are given in
parentheses. ***P , 0.001 versus R1-wt controls; yyyP , 0.001 comparing
GluR1 1 CTZ versus GluR1-L497Y; zzzP , 0.001 comparing GluR1-
L497Y in the absence and presence of CTZ. Unpaired t-tests were used with
Bonferroni correction for multiple comparisons.
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to its positive allosteric effect (i.e., slower desensitization) at
L497Y receptors could not have been predicted. We ques-
tioned whether these counteractive secondary effects were
unique to CTZ. We ﬁrst examined the actions of TCM, a
congener of CTZ, on L/Y mutant receptors. TCM is also a
positive allosteric modulator of AMPA-type channels, but it
is not as potent as CTZ (21,36). Little is known about the
binding of TCM, but the fact that TCM and CTZ are
benzothiadiazides having similar structures and activities
suggests they bind to a common site at the GluR1 dimer
interface. In agreement with previous studies (21,36), TCM
(500 mM) slowed GluR1 wild-type desensitization by sev-
enfold and increased the steady-state currents to nearly 90%
of peak (Fig. 4 A). This concentration of TCM did not alter
the nondesensitizing phenotype of GluR1-L497Y mutant
receptors but did signiﬁcantly increase the rate of GluR1-
L497Y deactivation and produced a rightward shift in the
concentration-response curve (Fig. 4 and Table 1). These
actions of TCM were qualitatively similar in all respects to
CTZ, and the results therefore support the hypothesis that the
two drugs share a common binding site and mechanism of
action. Notably, TCM was ineffective at GluR1-S750Q mu-
tant receptors, and its effects were generally less robust than
CTZ (Table 1). These differences may correspond to the
lower afﬁnity of the congener or to differences in the rela-
tive efﬁcacies of the modulators on the various processes
examined.
To conﬁrm that the triad of effects displayed by CTZ on
GluR1 receptors (slower desensitization, and counteractive
effects on deactivation and EC50) was unique to benzothi-
adiazides, we investigated another family of positive allo-
steric modulators. CX614 is a benzamide that belongs to a
family of modulators known collectively as Ampakines
(37,38). Ampakines also potentiate AMPAR currents but
are believed to do so predominantly by slowing the rate
of channel closing, although to a lesser extent they also
inhibit desensitization (7,28,39). At a concentration of 100
mM, CX614 slowed desensitization of wild-type GluR1 by
twofold, increased the nondesensitizing steady-state currents
(from ,1% before drug treatment to 39 6 4% after
treatment), and slowed deactivation by 2.5-fold (n ¼ 5)
(Fig. 4 A). CX614 also slowed deactivation of L497Y mutant
receptors by nearly twofold (Fig. 4, C and D). Similar results
were obtained with 3 mM aniracetam, a ﬁrst-generation
Ampakine, at L497Y mutant receptors (tdeact 21 6 2 ms).
Despite the marked slowing of deactivation in the presence
of CX614, no appreciable change was observed in the
L497Y glutamate concentration-response curve (Fig. 4, E
and F). Such profound slowing of deactivation without a
concomitant change in EC50 is not consistent with changes
to agonist dissociation rates (koff) but is consistent with
slower channel-closing rates (a). These data corroborate
conclusions that have been made regarding the actions of
aniracetam and CX614 on GluR2 ﬂip and GluR1–3 ﬂop
splice variants (7,28,38).
FIGURE 3 Negative allosteric actions of CTZ require the S750 residue.
(A) Wild-type GluR1 and GluR1-S750Q mutant responses to 50-ms ap-
plication of 10 mM glutamate are overlaid to compare desensitization
kinetics. The GluR1-S750Q mutant was unaltered after treatment with 100
mM CTZ. (B) The GluR1-L497Y mutant and GluR1-L497Y/S750Q double
mutant responses to 50-ms application of 10 mM glutamate are overlaid
to compare desensitization kinetics. Note that the GluR1-L497Y/S750Q
double mutant exhibits some desensitization (average ;27%), which is
absent or slower in the L/Y parent. GluR1-L497Y/S750Q mutant kinetics
were unaltered after treatment with 100 mM CTZ. (C) Deactivation kinetics
of the GluR1-S750Q mutant receptor are similar in the absence and presence
of 100 mM CTZ. Traces are pre- and postdrug responses to 1-ms
applications of 10 mM glutamate. The GluR1-wt trace is provided for
reference. (D) Deactivation kinetics of the GluR1-L497Y/S750Q double
mutant are unaltered by 100 mM CTZ. The overlay is provided for direct
comparison of pre- and postdrug kinetics and the GluR1-wt response. (E)
Summary bar plot comparing the desensitization time constants of GluR1
wild-type and mutant receptors. Error bars represent SEM. Numbers of
observations are given in parentheses. The GluR1-L497Y/S750Q double
mutant receptor displayed a partial block of desensitization (73 6 3%
nondesensitizing); tdes of the remaining decay from peak to steady state was
16.4 6 0.4 ms. ND indicates the majority of current was nondesensitizing
during 50-ms agonist pulses. (F) Summary bar plot comparing deactivation
time constants for GluR1-S750Q and GluR1-L497Y/S750Q double mutant
receptors in the absence and presence of CTZ. Error bars represent SEM.
Numbers of observations are given in parentheses. Pre- and postdrug mea-
sures were not signiﬁcantly different for either receptor by paired t-tests. A
signiﬁcant difference was disclosed only between GluR1-S750Q and GluR1-
L497Y/S750Q (**P, 0.01, unpaired t-test with Bonferroni correction).
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Modeling of modulator and mutation effects on
AMPA channel function
To further inform conclusions about the effects of modula-
tors and mutations on AMPAR gating, we simulated their
actions by computational modeling. We began with a sim-
pliﬁed version of the Robert and Howe model (29), as shown
in Fig. 5, which includes four binding sites linked to three
subconductance states displayed by AMPARs (31,34). The
assumptions of the model have been described (29), and the
kinetic rate constants that were derived for GluR1-wt (Table
2) produced an accurate simulation of the GluR1-wt phe-
notype (tdes 2.1 ms, tdeact 0.8 ms, and 597 mM EC50) (Fig.
5, B and C).
We ﬁrst determined the minimum changes necessary to
reduce the rate and extent of desensitization to simulate
GluR1 1 CTZ and GluR1-L497Y. A ‘‘nondesensitizing’’
phenotype was replicated in several ways, including slowing
entry into the desensitized states (kdes), accelerating exit from
the desensitized states (kres), or simply eliminating the desen-
sitized states. Changing kdes and kres had complementary
effects except that kres primarily impacts the magnitude of the
steady-state current, whereas kdes governs the rate of decay
FIGURE 4 Effects of other allosteric modulators on GluR1-L497Y receptors. (A) Responses of GluR1 wild-type to 1- and 50-ms pulses of 10 mM glutamate
in the absence and presence of other positive allosteric modulators. Traces are averages of 5-10 consecutive responses measured under control conditions and
after preincubation with 100 mM CTZ, 500 mM TCM, or 100 mM CX614. (B) Responses of GluR1-L497Y receptors to 1- and 50-ms pulses of 10 mM
glutamate under control conditions and after preincubation with 500 mM TCM or 100 mM CX614. (C) Traces are superimposed to compare deactivation
kinetics of GluR1-L497Y (1-ms pulse of 10 mM glutamate) under control conditions and after preincubation with TCM or CX614. (D) Summary bar plot of
deactivation time constants. Error bars represent SEM. Numbers of observations are given in parentheses. **P, 0.01, ***P, 0.001 versus L497Y receptors
in the same patches before drug treatment (paired t-tests). Note that deactivation after exposure to CX614 was biexponential; a weighted t of 21.96 1.4 ms is
plotted. (E) Concentration-response curves for GluR1-L497Y receptors in the absence and presence of modulators. Data are ﬁt by the logistic equation (see
Methods); error bars represent SEM for individual data points. Note the moderate rightward shift in the presence of TCM, which was not observed in the
presence of CX614. The logistic ﬁt to TCM data had an unusually shallow slope with a Hill coefﬁcient of 0.7, as compared to values of 1.2 to 1.4 in most other
cases. (F) Summary bar plot of agonist potency under control and drug conditions. Error bars represent SEM. Numbers of observations are given in
parentheses. Best-ﬁtting EC50 values were determined for individual patches. ***P, 0.001 versus untreated L497Y receptors (unpaired t-test with Bonferroni
correction).
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from peak to steady state and has greater impact on the peak
current amplitudes. Changing these rates together gave the
best approximation of CTZ effects (40-fold slower kdes,
4-fold faster kres), whereas slowing kdes alone by 150-fold
was sufﬁcient to model the L/Y mutant currents. These mo-
diﬁcations gave the best approximation of CTZ and L/Y mu-
tant currents having an initial peak and slow decay to a
steady-state level at ;80% of peak.
Regardless of how the ‘‘nondesensitizing’’ phenotype was
modeled, reducing or eliminating desensitization from the
model by itself predicted very little change in either tdeact
(0.8 to 1.0 ms) or EC50 (570 to 416 mM). In addition to
alterations in kdes/kres, more realistic models of CTZ and L/Y
mutation effects on these measures required additional
changes to agonist dissociation rates (koff). They could not
be reproduced by slowing channel-closing rates (a), which
slowed deactivation but did not lower the agonist EC50.
CTZ effects on GluR1 were best simulated having 3.6-fold
slower koff than wild type (tdeact 2.3 ms, EC50 125 mM), and
L/Y mutation effects required a 20-fold slower koff (tdeact
13.9 ms, EC50 25 mM). All other modulator and mutation
effects, except for CX614, were readily simulated by alter-
ing these same rates (Fig. 5, B and C, and Table 1). The addi-
tive effects of CTZ on L/Y mutant desensitization were
reproduced in the L/Y model having fourfold faster kres, as in
the CTZ model, whereas the acceleration of deactivation and
reduction of agonist potency by CTZ was readily simulated
by increasing koff in the L/Y model by threefold (tdeact 3.84
ms, EC50 71 mM). The best-ﬁtting model describing the
behavior of the L/Y-S750Q double mutant receptor required
20-fold slower kdes, sixfold faster kres, and 30% faster koff as
compared to GluR1-wt. Notably, the small change in koff
made here was also sufﬁcient to produce the slight increase
in EC50 and faster tdeact and tdes seen for the GluR1-S750Q
mutant (7) (Table 1).
In contrast to these, the preferential effects of CX614 on
deactivation with lesser effect on agonist EC50 were repro-
duced by slowing channel closing rates threefold in the wild-
type model. This change alone slowed tdes and tdeact 2.6-fold
because both are measured as decay of current from the open
states and are therefore limited by channel closing. Truly
accurate simulations also required ﬁvefold faster kres to repro-
duce the larger equilibrium currents associated with CX614
without further slowing of desensitization (28) (Table 1).
Our experimental results can therefore be reasonably
well described by modiﬁcations to existing models of GluR
function. Within the context of these models, the multiple
FIGURE 5 Computational simulations of modulatory effects. (A) Kinetic
scheme of the four-site model used for simulations. The form of the model
and starting rate constants were adapted from Robert and Howe (29), where
R represents receptors in the closed, activatable state, D represents the de-
sensitized receptor state, O represents the open-channel state, and subscripted
numbers indicate the number of agonist molecules bound in the various
states. O2, O3, and O4 conductance levels were 8, 15, and 23 pS, respec-
tively. Agonist binding (k1) and unbinding (k) reactions are indicated by
right and left arrows. Channel-opening (b), -closing (a), desensitization (d),
and resensitization (g) reactions are indicated by up or down arrows.
Optimized reaction rates are given in Table 2. (B) Simulated current traces
comparing the kinetics of deactivation (1 ms agonist pulses, left) and
desensitization (50 ms agonist pulses, right) of the models after optimization
of model parameters to match experimental results. (C) Simulated concen-
tration-response curves from the optimized models. Peak currents were
measured from 50-ms simulations, normalized, and plotted relative to their
individual maxima. Data are ﬁt with the logistic equation (see Methods).
Best-ﬁtting EC50 values are given in the ﬁgure.
TABLE 2 Optimized parameters for Fig. 5 simulations
Rate Control* CTZ L/Y L/Y 1 CTZ L/Y, S/Q CX614
k1 (mM1/s1) 20 20 20 20 20 20
k (s1) 9000 2500 450 1500 12,000 9000
k2 (s1) 0.41 0.41 0.41 0.41 0.41 0.41
a (s1) 1550 1550 1550 1550 1550 500
b (s1) 8000 8000 8000 8000 8000 8000
g0 (s1) 1 1 1 1 1 1
g (s1) 7.6 60 7.6 30 46 38
d0 (s1) 0.03 0.03 0.03 0.03 0.03 0.03
d (s1) 1800 45 12 12 90 1800
*Control starting values were taken from Robert and Howe (29).
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effects of modulators and even the single-point mutations
cannot be simulated by changes to desensitization alone
(kdes/kres) but require additional changes to agonist dissoci-
ation (koff) or channel closing (a).
DISCUSSION
AMPAR gating
Emerging interest in the development of AMPAR allosteric
modulators as potential therapeutics makes it increasingly
important to understand both the effects of lead compounds
and the nature of the gating processes theymodulate. AMPAR
gating is an allosteric process by which glutamate binding
promotes conformational transitions from closed to open and
desensitized channel states. Although the molecular details of
channel opening and desensitization are unclear, it has been
proposed that closure of the ligand-binding domain around
ligand pulls against a rigid dimer interface to cause opening of
the channel pore. Desensitization is thought to result from
disintegration of the dimer interface, which uncouples ligand
binding from channel opening. Functional and atomic-level
structural analyses support this model of AMPAR gating
(11–14,28,29,40,41). Mutations that promote stability of the
dimer interface slow desensitization, as in the case of L497Y,
whereas mutations that destabilize the dimer interface accel-
erate desensitization (12,14,40). CTZ binds to speciﬁc
residues within the dimer interface to promote dimer stability
and slow desensitization (7,11).
Modulator and mutation effects on channel gating
The structural model does not explain why the effects of
modulators and mutations that stabilize the dimer interface
are not limited to desensitization. Rather, such manipulations
tend to produce a constellation of effects, simultaneously
altering deactivation, desensitization, and agonist potency.
These secondary effects on deactivation and agonist potency
might result in part or entirely from the slowing of desen-
sitization itself, to the extent that desensitization limits chan-
nel activation at low agonist concentrations and provides a
route of inactivation from the ligand-bound and possibly
open states. Otherwise, they might reﬂect secondary actions
of drugs and mutation on channel-closing (a) or agonist dis-
sociation (koff) rates that are entirely independent of effects
on desensitization. If the former were true, we hypothesized
that block desensitization by any means should have quan-
titatively similar effects on deactivation and agonist EC50.
Moreover, these effects of modulators should be occluded in
cases where desensitization is already blocked by mutation.
To test these predictions, we compared the effects of CTZ
and TCM on GluR1-wt and GluR1-L497Y mutant receptors.
Consistent with previous reports, CTZ, TCM, and L/Y mu-
tation profoundly slowed desensitization of GluR1 during
prolonged exposure to agonist (7,27,34,36). Yet, despite the
near absence of desensitization during test pulses, these
treatments had quantitatively very different effects on deac-
tivation and glutamate potency (see Table 1). Furthermore,
although CTZ and TCM further slowed desensitization in the
L/Y mutant, they paradoxically accelerated deactivation and
reduced agonist potency, opposite their normal effects on
GluR1-wt. Results therefore indicate that the effects on
deactivation and agonist potency are not a consequence of
slower desensitization. Predictions of computational models
support this conclusion and further suggest that CTZ, TCM,
and L/Y mutation alter desensitization (kdes/kres) and agonist
binding (koff) independently. The effects on kdes/kres most
likely involve greater dimer stability, whereas the modula-
tion of koff appears to involve interactions with the S750
residue speciﬁcally. Greatest support for this conclusion
comes from the L497Y-S750Q double mutant where S/Q
mutation restores L/Y mutant deactivation and EC50 to wild-
type levels.
Aniracetam and CX614 are unique from CTZ and TCM.
These modulators bind between the lower lobes of the ligand-
binding domain within the dimer interface, where they inhibit
the relaxation from the closed- to open-cleft conﬁguration
(28). These and related benzamide modulators generally slow
receptor deactivation with relatively less effect on desensi-
tization or agonist potency. Their actions persist in the L497Y
and S750Q mutants and are best modeled by assuming faster
recovery from desensitization and slower channel closing
(7,28,37,38,42).
Alternative interpretations of results
There are several possible explanations for the conﬂicting
actions of these modulators on deactivation and agonist po-
tency in the L/Y mutant. One interpretation is that modu-
lator-receptor interactions supersede interactions made by
the mutant tyrosine residue so that L/Y mutant and wild-type
receptors behave similarly when bound to modulators. In-
deed, tdeact and EC50 values of WT1 CTZ (or TCM) and L/
Y 1 CTZ (or TCM) are more similar than those of L/Y
receptors in the absence and presence of modulators (Table
1). However, several observations contradict this explana-
tion. First, both modulators further slowed desensitization of
L/Y mutant receptors. The additive nature of effects suggests
that both the modulator and L/Y interactions across the dimer
interface remain intact. Second, tdeact and EC50 values are
signiﬁcantly different between WT 1 CTZ (TCM) and L/Y
1 CTZ (TCM), in some cases by two- to threefold. Un-
fortunately, the L/Y 1 CTZ crystal structure has not been
solved, which might further refute this explanation. More
limited insight may be gained by comparison of related
structures, including GluR21AMPA (PDB: 1FTM), GluR2
1GLU1 CTZ (PDB: 1LBC), and GluR2-L483Y1AMPA
(PDB: 1LB8) (10,11). Superimposition of these structures
indicates that the L/Y residue is 8 to 8.7 A˚ from the nearest
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point of CTZ, suggesting there is unlikely to be any direct
interaction between the L/Y residue and modulators. Exam-
ination of all residues within 4 A˚ of CTZ, the L/Y residue, or
the bound agonist in the superimposed structures reveals
only minuscule differences in the position or orientation of
these residues that cannot account for the profound effects of
CTZ or TCM on L/Y deactivation and agonist potency. We
could ﬁnd no indication that CTZ supersedes any direct
interactions made by the L/Y residue.
A more plausible explanation for the seemingly paradox-
ical actions of modulators on L/Y mutant receptors is that
CTZ and TCM have two opposing actions. The ﬁrst is to
block desensitization, which by itself only modestly slows
deactivation and increases agonist potency. The second is to
destabilize agonist binding, which accelerates deactivation
and decreases agonist potency. Quantitative differences among
CTZ, TCM, and L/Y mutation effects and their paradoxical
interactions can thus be explained by how effectively these
manipulations engage the two processes. Some previous stud-
ies have alluded to a second inhibitory action of CTZ that
occurs independently of desensitization. Patneau et al. (43)
noted a modest inhibition of kainate-evoked currents in
native GluRs from hippocampal neurons. Others have re-
ported reduced afﬁnities for radioligands binding to native or
recombinant AMPARs treated with CTZ (44,45) and an
approximately twofold increase in the agonist EC50 at some
nondesensitizing GluR chimeras (27). These data are most
consistent with effects on agonist dissociation (koff). All of
the effects on desensitization, deactivation, and EC50 can be
attributed to a single CTZ binding site because they are abol-
ished by the S750Q mutation (7,11). Moreover, the profound
slowing of desensitization in the L/Y-S750Q double mutant
without effects on tdeact or EC50 argue that the S750 residue
is directly involved in modulation of koff in addition to its
being required for modulator binding.
The role of S750 in modulation
S750Q mutation in wild-type GluR1 has only a modest im-
pact on receptor function (7,11,23). Such a profound effect
on L/Y mutant receptor function is therefore quite remark-
able. Sun et al. (11) reported a similar, slowly desensitizing
phenotype for the GluR2-L483/S754D double mutant. These
mutations target the same sites we examined in GluR1 except
that the S/D mutation alone accelerates desensitization more
than S/Q (7,11); tdeact and EC50 values were not available
for comparison. The authors concluded that these two residues
act independently to regulate the transitions into and out of
the desensitized states. Our results support their conclusion
with respect to the rate and extent of desensitization, which
we agree is most readily explained by the effects of these
mutations on dimer stability. On the other hand, these res-
idues clearly interact with respect to deactivation and agonist
potency. In fact, our data suggest that the S750 residue is
essential for modulation of koff by L/Y mutation. Unfortu-
nately, because this residue is required for CTZ binding, its
downstream involvement in benzothiadiazide modulation
cannot be ascertained. Nonetheless, the L/Y-S750Q double
mutant clearly demonstrates that desensitization can be
modiﬁed independently of deactivation, at least by muta-
genesis targeting the dimer interface.
Future design of more selective modulators
Insights from comparison of these modulators and mutations
may offer strategies to more selectively target desensitization
or other functional measures. CTZ and TCM differ by an R3
substitution, which differentiates their size, hydrophobicity,
and charge. It may be signiﬁcant that that the R3 moiety
occupies a hydrophobic pocket near the L/Y residue (11).
Although CTZ and TCM have substantially different af-
ﬁnities for AMPARs, both produce similar block of desen-
sitization. More importantly, their modulatory effects on
tdeact and EC50 are signiﬁcantly different, suggesting that
other R3 substitutions may provide a means to selectively
target these parameters. Numerous benzothiadiazides have
been described, including additional R3 substitutions, some
of which slow AMPAR desensitization (21). Aside from
CTZ and the present characterization of TCM, none of these
compounds has been thoroughly examined for effects on
AMPAR deactivation or agonist potency. Additional char-
acterization of this family of compounds could be useful in
the generation of more functionally selective modulators that
would have both experimental utility in dissecting GluR
function and therapeutic value in correcting GluR dysfunc-
tion in disease.
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